Ocuphire to Participate in March Investor Conferences

Rhea-AI Summary

Ocuphire Pharma (Nasdaq: OCUP) announces participation in two upcoming conferences. CEO Mina Sooch will present at the HC Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 am ET, and at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 9:20 am ET. Both presentations will be available via webcast. Ocuphire focuses on developing therapies for eye disorders, including its lead product Nyxol, which targets pupil constriction and has undergone extensive clinical trials. The company explores partnerships for further development.

HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th
Oppenheimer Healthcare Conference at 9:20 am ET on March 18th

FARMINGTON HILLS, Mich., March 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, President and Chief Executive Officer, will participate in the following conferences in the month of March and invites investors to join by webcast. Please see details below:

H.C. Wainwright: Global Life Sciences Conference (Virtual)

Title:	Ocuphire Pharma (OCUP) Company Presentation
Date:	Tuesday, March 9th, 2021
Time:	7:00 am Eastern Time
Presenter:	Mina Sooch, CEO
Webcast:	On-demand starting at 7am ET on 3/9

Oppenheimer 31st Annual Healthcare Conference (Virtual)

Title:	Ocuphire Pharma (OCUP) Company Presentation
Date:	Thursday, March 18th, 2021
Time:	9:20 am Eastern Time
Presenter:	Mina Sooch, CEO
Webcasting Link:	https://wsw.com/webcast/oppenheimer9/ocup/2737603

If you are interested in arranging a one-on-one meeting request, please contact your bank conference representative or ir@ocuphire.com. Presentations are available on the Investors section of Ocuphire’s corporate website in the Events section.

About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol^® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 7 Phase 1 and 2 trials. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME), and has been studied in 11 Phase 1 and 2 trials. Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 clinical trials and ongoing Phase 3 registration trials (NCT04620213 and NCT04638660), Phase 2 trial in presbyopia (NCT04675151) and soon to recruit Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates, results of ongoing and future clinical trials, and commercialization and market opportunities. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, and (ix) the success and timing of commercialization of any of Ocuphire’s product candidates. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Ocuphire Contacts

Mina Sooch, President & CEO 
Ocuphire Pharma, Inc. 
ir@ocuphire.com
www.ocuphire.com 

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com

FAQ

What conferences will Ocuphire Pharma (OCUP) participate in March 2021?

Ocuphire Pharma will participate in the HC Wainwright Global Life Sciences Conference on March 9, 2021, and the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021.

Who will present for Ocuphire Pharma at the upcoming conferences?

Mina Sooch, President and CEO, will present for Ocuphire Pharma at both conferences.

What is the significance of Ocuphire's Nyxol product candidate?

Nyxol is a lead product candidate designed to treat several eye conditions, including reducing pupil size and improving night vision.

How can investors access Ocuphire Pharma's presentations?

Investors can access the presentations via webcasts starting at the scheduled times for each conference.

When is Ocuphire's presentation at the HC Wainwright Conference?

Ocuphire's presentation at the HC Wainwright Global Life Sciences Conference is scheduled for March 9, 2021, at 7:00 am ET.

When is Ocuphire's presentation at the Oppenheimer Healthcare Conference?

Ocuphire's presentation at the Oppenheimer Healthcare Conference is on March 18, 2021, at 9:20 am ET.